Occam is pleased to announce the placement of Andreas Grauer as the CMO of Federation Bio, a Venrock-backed, next generation microbiome company based on the work of prolific Stanford academic Michael Fischbach pioneering a novel approach to create potent, durable and safe cell therapies.

Grauer, a highly tenured physician scientist and entrepreneurial executive with formidable clinical development experience across modalities and disease states, will be instrumental in giving shape to the dynamic microbial platform as FedBio enters the clinic with its lead program in 2022.

Grauer previously served as CMO at Corcept, overseeing clinical development programs in endocrinology and oncology, as well as metabolic and neurologic indications. Prior to Corcept, Dr. Grauer served as Vice President of Global Development at Amgen, leading clinical research efforts in bone, nephrology and inflammation. While at Amgen, he oversaw several large development programs spanning from early clinical research to FDA and international approvals and commercialization.

Grauer is an internist and endocrinologist by training. He received his medical education at the University of Heidelberg in Germany and at the Royal Postgraduate Medical School at the Hammersmith Hospital in London, UK, conducting subsequent clinical training at the University of Heidelberg. Dr. Grauer has authored more than 100 scientific publications and book chapters.